The downregulation of CMKLR1 in Kupffer cells by a phosphatidyl inositol 3-kinase inhibitor improved hepatic insulin resistance and inflammation, suggesting that the chemerin–CMKLR1 signaling pathway contributes to metabolic disease in obesity by modulating the function of these immune cells [64]. Here, RARRES2 is linked to Other metabolic disease.